# Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct01582230` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01582230](<https://clinicaltrials.gov/study/NCT01582230>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01582230

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 293 participants.

## Technical summary

Registry record NCT01582230. Randomized; double masking; primary purpose treatment. Start 2012-04 (registry gives no type); primary completion 2013-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 293 participants (enrolled count; ClinicalTrials.gov record NCT01582230, source copy `cardio:ctgov-nct01582230-2013-08-30`, retrieved 2026-10-26)
- Start date: 2012-04 (registry gives no type) (ClinicalTrials.gov record NCT01582230, source copy `cardio:ctgov-nct01582230-2013-08-30`, retrieved 2026-10-26)
- Primary completion: 2013-05 (actual) (ClinicalTrials.gov record NCT01582230, source copy `cardio:ctgov-nct01582230-2013-08-30`, retrieved 2026-10-26)
- Completion: 2013-05 (actual) (ClinicalTrials.gov record NCT01582230, source copy `cardio:ctgov-nct01582230-2013-08-30`, retrieved 2026-10-26)
- Countries: China; Philippines; Singapore; Thailand (ClinicalTrials.gov record NCT01582230, source copy `cardio:ctgov-nct01582230-2013-08-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01582230-2013-08-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Vildagliptin
- Intervention (Drug): Placebo
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: f4bef4052d38eae84f6a803a07f20204b859de6176dd0bb7f64a89d2d694cb44
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
